Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib

Lynn Quek(University of Oxford), Muriel D. David(Inserm), Alison Kennedy(University of Oxford), Marlen Metzner(University of Oxford), Michael Amatangelo, Alan H. Shih(Memorial Sloan Kettering Cancer Center), Bilyana Stoilova(University of Oxford), Cyril Quivoron(Inserm), Maël Heiblig(Inserm), Christophe Willekens(Inserm), Véronique Saada(Inserm), Samar Alsafadi(Inserm), M. S. Vijayabaskar(Wellcome Sanger Institute), Andy Peniket(Oxford University Hospitals NHS Trust), Olivier Bernard(Inserm), Sam Agresta(Agios Pharmaceuticals (United States)), Katharine Yen(Agios Pharmaceuticals (United States)), Kyle J. MacBeth, Eytan M. Stein(Memorial Sloan Kettering Cancer Center), George S. Vassiliou(University of Cambridge), Ross L. Levine(Memorial Sloan Kettering Cancer Center), Stéphane de Botton(Inserm), Anjan Thakurta(Bristol-Myers Squibb (Switzerland)), Virginie Penard‐Lacronique(Inserm), Paresh Vyas(University of Oxford)
Nature Medicine
July 13, 2018
10.1038/s41591-018-0115-6
Cited by 197Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis